Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Altimmune (ALT) 10K Form and Latest SEC Filings 2026

Altimmune logo
$2.84 +0.03 (+0.89%)
As of 01:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Altimmune SEC Filings & Recent Activity

Altimmune (NASDAQ:ALT) has submitted 413+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Altimmune's financial statements. The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026.

Form 4
Altimmune, Inc. Reports Ownership Change on May. 1, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Altimmune Files Current Report on May. 13, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Altimmune Files Annual Report on Mar. 6, 2026

The 10-K contains Altimmune's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Altimmune SEC Filing History

Browse Altimmune's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/15/2026 3:15 PM
Altimmune (1326190) Subject
TANG CAPITAL MANAGEMENT LLC (1232621) Filed by
Form SCHEDULE 13G/A
05/13/2026 3:17 PM
Altimmune (1326190) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
05/13/2026 6:34 AM
Altimmune (1326190) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/12/2026 8:46 AM
Altimmune (1326190) Subject
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Form SCHEDULE 13G
05/01/2026 4:38 PM
Altimmune (1326190) Subject
VIKING GLOBAL INVESTORS LP (1103804) Filed by
Form SCHEDULE 13G
05/01/2026 3:36 PM
Altimmune (1326190) Subject
TCG Crossover GP II, LLC (1969280) Filed by
Form SCHEDULE 13G
05/01/2026 3:16 PM
Altimmune (1326190) Issuer
Schafer Klaus (1705904) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 3:18 PM
Altimmune (1326190) Issuer
Jorkasky Diane (1527204) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 3:20 PM
Altimmune (1326190) Issuer
Sohn Catherine A. (1555132) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 3:05 PM
Altimmune (1326190) Issuer
SAYARE MITCHEL (1201196) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2026 3:05 PM
Altimmune (1326190) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/23/2026 8:29 PM
Altimmune (1326190) Filer
Form 424B5
04/22/2026 8:15 PM
Altimmune (1326190) Filer
Form S-3MEF
04/22/2026 4:24 PM
Altimmune (1326190) Filer
Form 424B5
04/16/2026 4:07 PM
Altimmune (1326190) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/01/2026 3:05 PM
Altimmune (1326190) Issuer
WEAVER GREGORY L (1251779) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2026 2:23 PM
Altimmune (1326190) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/17/2026 6:13 AM
Altimmune (1326190) Filer
Form ARS
03/17/2026 6:05 AM
Altimmune (1326190) Filer
Form DEF 14A
03/09/2026 6:00 AM
Altimmune (1326190) Issuer
Durso Jerome Benedict (1698665) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/09/2026 6:05 AM
Altimmune (1326190) Issuer
WEAVER GREGORY L (1251779) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 6:56 AM
Altimmune (1326190) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/06/2026 7:01 AM
Altimmune (1326190) Filer
Form PRE 14A
03/05/2026 6:08 AM
Altimmune (1326190) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/02/2026 3:10 PM
Altimmune (1326190) Issuer
Jordt Raymond M (1960780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/30/2026 12:25 PM
Altimmune (1326190) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
01/29/2026 3:15 PM
Altimmune (1326190) Issuer
Jordt Raymond M (1960780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/28/2026 4:23 PM
Altimmune (1326190) Filer
Form 424B5
01/28/2026 4:26 PM
Altimmune (1326190) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/27/2026 6:00 AM
Altimmune (1326190) Issuer
Roberts M Scot (1705905) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 6:05 AM
Altimmune (1326190) Issuer
Garg Vipin K (1515813) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 6:10 AM
Altimmune (1326190) Issuer
Jordt Raymond M (1960780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2026 3:10 PM
Altimmune (1326190) Issuer
Pisano Wayne (1743611) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 3:05 PM
Altimmune (1326190) Issuer
Sohn Catherine A. (1555132) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 3:10 PM
Altimmune (1326190) Issuer
Jorkasky Diane (1527204) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2025 3:10 PM
Altimmune (1326190) Issuer
Durso Jerome Benedict (1698665) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 5:30 AM
Altimmune (1326190) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/07/2025 11:15 PM
Altimmune (1326190) Filer
Form EFFECT
12/01/2025 7:38 PM
Altimmune (1326190) Issuer
Durso Jerome Benedict (1698665) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 7:00 AM
Altimmune (1326190) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2025 4:26 PM
Altimmune (1326190) Filer
Form S-3/A
ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad)

The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel

11/12/2025 3:07 PM
Altimmune (1326190) Issuer
WEAVER GREGORY L (1251779) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2025 3:47 PM
Altimmune (1326190) Filer
Form S-3
Registration statement under Securities Act of 1933  
11/06/2025 3:10 PM
Altimmune (1326190) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2025 6:04 AM
Altimmune (1326190) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2025 3:24 PM
Altimmune (1326190) Issuer
WEAVER GREGORY L (1251779) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/29/2025 3:13 PM
Altimmune (1326190) Issuer
Hodges Philip (1705562) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/29/2025 3:14 PM
Altimmune (1326190) Issuer
SAYARE MITCHEL (1201196) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/29/2025 3:15 PM
Altimmune (1326190) Issuer
Schafer Klaus (1705904) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/29/2025 3:17 PM
Altimmune (1326190) Issuer
GILL JOHN (1409939) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/29/2025 3:18 PM
Altimmune (1326190) Issuer
Jorkasky Diane (1527204) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/29/2025 3:12 PM
Altimmune (1326190) Issuer
Pisano Wayne (1743611) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2025 3:07 PM
Altimmune (1326190) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/17/2025 3:38 PM
Altimmune (1326190) Issuer
Richardson Linda M (1595064) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/17/2025 3:36 PM
Altimmune (1326190) Issuer
Richardson Linda M (1595064) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/12/2025 9:15 AM
Altimmune (1326190) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/12/2025 6:10 AM
Altimmune (1326190) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/16/2025 6:02 PM
Altimmune (1326190) Subject
BlackRock, Inc. (2012383) Filed by
Form SCHEDULE 13G/A
06/26/2025 6:30 AM
Altimmune (1326190) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Altimmune SEC Filings - Frequently Asked Questions

Altimmune (ALT) has submitted 413+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Altimmune's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Altimmune's financial statements page.

The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:ALT) was last updated on 5/21/2026 by MarketBeat.com Staff.
From Our Partners